Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478592 | 0.81 | CA1 (0.42) | FFAR3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3657981 | 0.79 | CA2 (0.37) | FFAR3 | |
| SCHEMBL8477538 | 0.79 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL28294414 | 0.77 | CA1 (0.33) | SMN1; SMN2KMT2ALMNA | |
| SCHEMBL15549112 | 0.76 | TDP1 (0.38) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8431685 | 0.75 | NPSR1 (0.36) | — | |
| SCHEMBL24571484 | 0.74 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22208089 | 0.74 | MAPT (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21209461 | 0.74 | POLB (0.34) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29194219 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710660-B | DOT1L degradation agent and application thereof | 达纳-法伯癌症研究公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-112300172-B | Bruton tyrosine kinase inhibitors | 比奥根MA公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111263768-B | anticancer peptides | IDP研发制药有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-8680090-B2 | Sulfonyl containing benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-7943760-B2 | Non-nucleotide composition for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100197913-A1 | NON-NUCLEOTIDE COMPOSITION FOR INHIBITING PLATELET AGGREGATION | PLOURDE JR ROBERT | 2010-08-05 | — | — | US | disclosed |
| US-20100179137-A1 | PYRIDONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-7749980-B2 | Non-nucleotide compositions and method for treating pain | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749981-B2 | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7335648-B2 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1883637-A2 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | Inspire Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070123544-A1 | Non-nucleotide compositions and method for treating pain | INSPIRE PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2006119507-A2 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1685135-A1 | TETRAHYDRO-FURO¬3,4-D|DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION | Inspire Pharmaceuticals, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060121086-A1 | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | INSPIRE PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050267134-A1 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050159388-A1 | Non-nucleotide compositions and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005040174-A1 | TETRAHYDRO-FURO`3,4-D!DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION | INSPIRE PHARMACEUTICALS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039590-A1 | NON-NUCLEOTIDE COMPOSITIONS AND METHOD FOR TREATING PAIN | INSPIRE PHARMACEUTICALS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179137-A1 | PYRIDONE COMPOUND | PTGER4, P2RY4, PTGER1 | FFAR3 142/4885CHRM2 499/4885CHRM4 127/4885 |
| US-20050267134-A1 | Non-nucleotide composition and method for inhibiting platelet aggregation | P2RY12, P2RY11, P2RY13 | FFAR3 147/4885CHRM2 1570/4885CHRM4 1690/4885 |
| US-20100197913-A1 | NON-NUCLEOTIDE COMPOSITION FOR INHIBITING PLATELET AGGREGATION | P2RY12, P2RY13, P2RY11 | FFAR3 142/4885CHRM2 1554/4885CHRM4 1686/4885 |
| US-20070123544-A1 | Non-nucleotide compositions and method for treating pain | P2RX3, P2RX5, P2RX1 | FFAR3 220/4885CHRM2 716/4885CHRM4 921/4885 |
| US-20050159388-A1 | Non-nucleotide compositions and method for inhibiting platelet aggregation | P2RY12, P2RY11, P2RY13 | FFAR3 191/4885CHRM2 1493/4885CHRM4 1635/4885 |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | FFAR3 240/4885CHRM2 4367/4885CHRM4 4490/4885 |
| US-20060121086-A1 | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | P2RY12, P2RY11, P2RY13 | FFAR3 166/4885CHRM2 2313/4885CHRM4 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.